Clinical Trials

60 enrolled

Gynecologic

Endometrial Neoplasms

NCT04305054 2026-04-08

KEYMAKER-U02

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT07096609 2026-04-03

LONGIST

48 enrolled

Sarcoma

GIST

NCT06110793 2026-03-30

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

49 enrolled

Breast

Breast Neoplasms

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

GastrointestinalGenitourinaryThoracic

170 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

GastrointestinalGynecologic

301 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04977453 2026-03-17

Keynote B59

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04626479 2026-02-12

MK-3475-03A

400 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

144 enrolled

Carcinoma, Hepatocellular

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

90 enrolled

Phase 1/2 Not yet recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

116 enrolled

Advanced Hepatocellular Carcinoma (HCC)

NCT03526679 2025-12-05

LEADER

30 enrolled 9 charts

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT07149090 2025-11-20

Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

61 enrolled

Stomach Neoplasms

NCT04700072 2025-10-28

KEYMAKER-U02

56 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

DermatologicGastrointestinal

89 enrolled 24 charts

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

40 enrolled

Breast

Breast Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

320 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT04305041 2025-08-29

KEYMAKER-U02

100 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04626518 2025-07-25

KEYMAKER-U03

370 enrolled

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

53 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05774899 2025-06-17

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC